Further longitudinal experiments with samples from large, well-characterized cohorts of individuals with and without central nervous system diseases or under controlled conditions that modulate neurogenesis are required to validate this initial finding and to assess utility of CSF Gpc2 analysis in the clinic. The gene discussed is GPC2; the disease is central nervous system disorder.